CureVac NV (CVAC) Peer Comparison

$4.66

$0.00 (0.00%)

As on 06-Jan-2026 09:30EDT

Market cap

$1,049 Mln

Revenue (TTM)

$511 Mln

P/E Ratio

7

P/B Ratio

1

Div. Yield

0 %

Edit

	CureVac NV (CVAC)	Pharvaris BV (PHVS)	ProQR Therapeutics N.V. - ADR	InflaRx N.V. - ADR
Market cap ($ Mln)	1,049	2,546	330	309
Revenue (€ Mln)	511	--	19	0
Net Profit (€ Mln)	193.64	-171.57	-42.32	-39.14
Net Margin (%)	37.93	--	-228.38	387,532.08
RoE (%)	25.51	-59.98	-65.71	-41.72
Price to Earnings	6.96	--	--	--
Price-To-Book	1.03	7.34	3.48	1.76

Cashflow
Ratios

Cashflow (€ Mln)

	CureVac NV (CVAC)	Pharvaris BV (PHVS)	ProQR Therapeutics N.V. - ADR	InflaRx N.V. - ADR
Cash From Operating Activities	101.85	-120.13	-36.39	-48.56
Cash Flow from Investing Activities	-18.44	-0.54	-4.07	52.36
Cash from Financing Activities	-5.11	2.68	70.28	0.39
Net Cash Inflow / Outflow	--	--	--	--

Ratios

Profitability Ratios

	CureVac NV (CVAC)	Pharvaris BV (PHVS)	ProQR Therapeutics N.V. - ADR	InflaRx N.V. - ADR
ROCE (%)	25.06	-41.11	-31.67	-55.53
ROE (%)	25.51	-41.18	-40.40	-56.18
ROA (%)	16.67	-38.90	-17.02	-46.95
EBIT Margin (%)	-21.69	--	--	--
Net Margin (%)	37.93	--	-146.86	-27,784.96
Cash Profit Margin (%)	0.00	--	--	--

Growth Ratios

	CureVac NV (CVAC)	Pharvaris BV (PHVS)	ProQR Therapeutics N.V. - ADR	InflaRx N.V. - ADR
Revenue Growth (%)	-6.03	--	1.90	1.63
EBIT Growth (%)	-148.12	--	--	--
Net Profit Growth (%)	78.81	-33.06	1.27	-7.96
EPS Growth (%)	78.23	0.06	0.05	-0.08
Book Value Growth (%)	19.76	--	--	--

Valuation Ratios

	CureVac NV (CVAC)	Pharvaris BV (PHVS)	ProQR Therapeutics N.V. - ADR	InflaRx N.V. - ADR
Price / Earnings	4.72	-7.71	-7.80	-3.16
Price / Book Value	1.10	3.87	2.36	2.37
Dividend Yield (%)	--	--	--	--
EV/EBITDA	1.52	-5.19	-3.22	-2.05
Market Cap ($ Cr)	--	--	--	--

Solvency Ratios

	CureVac NV (CVAC)	Pharvaris BV (PHVS)	ProQR Therapeutics N.V. - ADR	InflaRx N.V. - ADR
Debt to Equity	0.00	0.00	0.18	0.01
Short term debt to equity ratio	0.00	0.00	0.05	0.01
Current Ratio	3.70	12.60	3.95	5.06
Quick Ratio	3.69	27.27	3.54	4.57
Interest Coverage	27.08	-4,977.62	-24.96	-2,228.93

Operating Efficiency Ratios

	CureVac NV (CVAC)	Pharvaris BV (PHVS)	ProQR Therapeutics N.V. - ADR	InflaRx N.V. - ADR
Debtors to sales (%)	3.84	--	11.10	1,046.71
Asset Turnover	0.44	0.00	0.12	0.00
Receivable days	24.71	--	33.81	6,088.16
Inventory Days	43.73	2,694.23	9.39	1,005.64
Payable days	112.69	6,434.88	2,900.45	468.85
Cash Conversion Cycle	-44.25	--	-1,139.22	6,624.95

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly